Efficacy and Safety of Immune Checkpoint Inhibitors in Treatment of 43 Cases with Recurrent,Persistent and Metastatic Cervical Squamous Cell Carcinoma
[Objective]To investigate the efficacy and safety of immune checkpoint inhibitors(ICIs)in treat-ment of recurrent,persistent and metastatic cervical squamous cell carcinoma.[Methods]Clinical data of 43 patients with recurrent,persistent and metastatic cervical squamous cell carcinoma treated by ICIs in Cancer Hospital of Chinese Academy of Medical Sciences,Cancer Hospital of Huanxing Chaoyang District,Tianjin Shixuenin General Hospital from January 2020 to August 2023 were retrospectively analyzed.The therapeutic efficacy was assessed according to RECIST 1.1 criteria and the side effects were assessed according to CTCAE 5.0 criteria.[Results]The median age of patients was 58(26～73)years old,the median treatment cycle was 4(1～21)and the median follow-up time was 12 months(1～52).The objective response rate was 39.5％and the disease control rate was 79.1％.The median progression-free survival was 13 months and the median overall survival was 32 months.Common adverse reactions inclueded leukopenia(48.8％),gastrointestinal reaction(32.6％),thrombocytopenia(18.6％),itching rash(16.3％),liver dysfunction(14.0％).The incidence of grade≥3 adverse reactions was 62.8％,including leukopenia,thrombocytopenia,gastrointestinal reactions,itching rash,hypothyroidism,hyperthyroidism,myocarditis,pneumonia,etc.One case terminated treatment due to adverse reactions,1 case was complicated with vaginal urethral fistula,and 1 case died of infection compli-cations.[Conclusion]ICIs have shown exciting efficacy in the treatment of recurrent,persistent,and metastatic cervical squamous cell carcinoma.However,we also need to pay close attention to its possible se-rious adverse reactions.
NETL
NSTL
万方数据
